MedTrace Logo

The Effect of Gait Training Using Different Slope Types on Balance in COPD Patients

NCT06644898 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-06-13

No results posted yet for this study

Summary

Although COPD is basically a respiratory system disease, its effects are not limited to the respiratory system. In this context, one parameter affected in COPD patients is balance. Recent studies have highlighted the importance of assessing balance and incorporating it into treatment options such as pulmonary rehabilitation. In this context, we aim to diversify the training by using different slope types (downhill, level, uphill) in aerobic exercise training, which is a strong component of pulmonary rehabilitation, and to evaluate the effect of slope type on balance. Testing different types of inclines in aerobic exercise training has the potential to result in different muscular gains. We anticipate that this may result in different balance gains.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

OTHER

Level walking training

For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.

OTHER

Downhill walking training

For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.

OTHER

Uphill walking training

For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.

Sponsors & Collaborators

  • Acibadem University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-09
Primary Completion
2026-06-01
Completion
2026-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06644898 on ClinicalTrials.gov